Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Naoto KatakamiTomoya MitaHidenori YoshiiToshihiko ShiraiwaTetsuyuki YasudaYosuke OkadaKeiichi TorimotoYutaka UmayaharaHideaki KanetoTakeshi OsonoiTsunehiko YamamotoNobuichi KuribayashiKazuhisa MaedaHiroki YokoyamaKeisuke KosugiKentaro OhtoshiIsao HayashiSatoru SumitaniMamiko TsugawaKayoko RyomotoHideki TakiTadashi NakamuraSatoshi KawashimaYasunori SatoHirotaka WatadaIichiro Shimomuranull nullPublished in: Cardiovascular diabetology (2020)
No IMT changes were observed between the tofogliflozin and the conventional treatment groups. However, tofogliflozin is a safe and effective treatment option for managing primary CVD risk factors in this population. Clinical Trial Registration UMIN000017607 ( https://www.umin.ac.jp/icdr/index.html ).